Axatilimab effects on skin in chronic graft-versus-host disease
Treatments studied
Part of Blood & lymphatic, Immune system & allergy, Skin clinical trials.
This study looks at how a medicine called axatilimab affects the skin in people with chronic graft-versus-host disease (a condition after a stem cell transplant). It compares people who take axatilimab with those who don't, using skin biopsies to see changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You have chronic graft-versus-host disease (cGVHD) that affects your skin.
- You will start taking axatilimab as part of your regular care, or you will not start it (for the control group).
- You can have a small skin sample taken (a biopsy) at the time you join.
- You do not have an active uncontrolled infection.
- You can give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (axatilimab) combined with a light-based blood treatment (ECP) for people with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It's for those who have already tried at least 2 other treatments or need high doses of steroids.
This study follows patients who have had a stem cell transplant and developed chronic graft-versus-host disease (a condition where transplanted cells attack the body). Researchers will track your symptoms and collect blood samples to understand what affects how well patients do over time.
This trial tests an experimental drug (ABSK021) for people with chronic graft-versus-host disease (cGvHD) after a stem cell transplant. It may help if other treatments haven't worked well enough.
This trial tests a medicine called an anti-CD25 antibody for people who have chronic graft-versus-host disease affecting the liver and whose condition did not improve with steroids. The treatment aims to calm the immune system and may help reduce liver damage.
This trial tests an experimental drug called Iguratimod for people with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It aims to see if the drug can safely control cGVHD symptoms when other treatments haven't worked well enough.
This study tests a new medicine called axatilimab, given after a stem cell transplant, to help prevent a common complication called graft-versus-host disease (GVHD), where the donor’s cells attack your body. If you are planning a transplant, this may help improve your recovery.
Hear when a new cGVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.